TB-500

Overview

Thymosin Beta-4 is a naturally occurring peptide that plays a crucial role in tissue repair and regeneration. It promotes cell migration, angiogenesis, and wound healing.

Reported benefits

Tissue repair, improved flexibility, reduced inflammation, enhanced recovery, hair growth stimulation

Protocols & dosing

Typical dosage: 2-5 mg (weekly).

Detailed dosing protocols have not yet been catalogued.

FDA & legal status

TB-500 is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed TB-500 from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place TB-500 on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 1 — July 23, 2026. PCAC agenda: BPC-157, KPV, TB-500, MOTS-c. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

Vendor information

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Side effects & safety

Reported side effects: Minimal side effects. Rare: headache, nausea, injection site reactions

References

No external sources have been catalogued for this article yet.